MedTrace Logo

PET Imaging of Brain mGluR5 Receptors Using [18F]SP203

NCT00538798 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-07-05

No results posted yet for this study

Summary

The metabotropic glutamate subtype five (mGluR5) receptor is a protein found in the brain and is the target for the excitatory chemical messenger glutimate. The purpose of this protocol is to measure mGluR5 receptors in the brain using positron emission tomography (PET) and a research drug called \[18F\]SP203.

Conditions

  • Healthy
  • Glutamate Receptor
  • mGlur5 Protein
  • Excitatory Amino Acid Receptors
  • Drug Kinetics
  • PET Scan

Interventions

DRUG

[18F]SP203

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    lead NIH

Principal Investigators

  • Masahiro Fujita, M.D. · National Institute of Mental Health (NIMH)

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-28
Completion
2015-03-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00538798 on ClinicalTrials.gov